Application effect research of different antihypertensive modes in elderly hypertensive patients with coronary heart disease and PCI

doi:10.11958/20221100

Abstract

CLC Number:

R544.1

Figures/Tables 6

References 12

[1]	RIVAS A M, PENA C, KOPEL J, et al. Hypertension and hyperthyroidism: association and pathogenesis[J]. Am J Med Sci, 2021, 361(1):3-7. doi:10.1016/j.amjms.2020.08.012.
[2]	NICHOLS S, MCGREGOR G, BRECKON J, et al. Current insights into exercise-based cardiac rehabilitation in patients with coronary heart disease and chronic heart failure[J]. Int J Sports Med, 2021, 42(1):19-26. doi: 10.1055/a-1198-5573.
[3]	GABA P, GERSH B J, ALI Z A, et al. Complete versus incomplete coronary revascularization: definitions,assessment and outcomes[J]. Nat Rev Cardiol, 2021, 18(3):155-168. doi:10.1038/s41569-020-00457-5.
[4]	ELCIK D, DURAN M, KELES OGLU Ş, et al. Effect of nondipper hypertension on coronary artery disease progression in patients with chronic coronary syndrome[J]. Turk J Med Sci, 2021, 51(3):1273-1280. doi:10.3906/sag-2011-225.
[5]	赵狄, 刘莉, RAHMAN M, 等. 直立性高血压与强化降压治疗:收缩压干预试验事后分析[J]. 中华高血压杂志, 2021, 29(1):99.
	ZHAO D, LIU L, RAHMAN M, et al. Orthostatic hypertension and intensive antihypertensive therapy:post hoc analysis of systolic blood pressure intervention trials[J]. Chin J hypertension, 2021, 29(1):99.
[6]	MAZIGHI M, RICHARD S, LAPERGUE B, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET):A multicentre,open-label,randomised controlled trial[J]. Lancet Neurol, 2021, 20(4):265-274. doi:10.1016/S1474-4422(20)30483-X.
[7]	OTT C, SCHMIEDER R E. Diagnosis and treatment of arterial hypertension 2021[J]. Kidney Int, 2022, 101(1):36-46. doi:10.1016/j.kint.2021.09.026.
[8]	郑刚. 老年高血压患者从强化降压治疗获益的临床新证据[J]. 中华老年心脑血管病杂志, 2022, 24(6):662-663.
	ZHENG G. New evidence of benefit from intensive antihypertensive therapy in elderly patients with hypertension[J]. Chin J Geriatr Heart Brain Ves Dis, 2022, 24(6):662-663.
[9]	刘宏瑜, 樊伟国, 苏海. 从血压测量方法差异评估不同研究中强化降压治疗的收缩压目标[J]. 中华高血压杂志, 2022, 30(7):620-621.
	LIU H Y, FAN W G, SU H. Evaluation of the systolic blood pressure target of intensive antihypertensive therapy in different studies based on the difference of blood pressure measurement methods[J]. Chin J Hypertens, 2022, 30(7):620-621. doi:10.16439/j.iSSN.1673-7245.2022.07.004.
[10]	ABRAHAM H M, WOLFSON L, MOSCUFO N, et al. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure,white matter lesions,and functional decline in older persons[J]. J Cereb Blood Flow Metab, 2016, 36(1):132-42. doi:10.1038/jcbfm.2015.121.
[11]	ZHANG W, ZHANG S, DENG Y, et al. Trial of intensive blood-pressure control in older patients with hypertension[J]. N Engl J Med, 2021, 385(14):1268-1279. doi:10.1056/NEJMoa2111437.
[12]	SPRINT Research Group, LEWIS C E, FINE L J, et al. Final report of a trial of intensive versus standard blood-pressure control[J]. N Engl J Med, 2021, 384(20):1921-1930. doi:10.1056/NEJMoa1901281.

组别	n		性别（男/女）	年龄（岁）	高血压类型（初发/既往）		高血压病程（年）		冠心病病程（年）		冠心病类型（稳定型心绞痛/ACS）			SBP （mmHg）		DBP （mmHg）		吸烟史	饮酒史
对照组	43		23/20	67.71±3.05	6/37		7.94±1.22		5.23±1.03		11（25.58）/32（74.42）			150.27±11.54		102.79±8.13		24（55.81）	17（39.53）
研究组	43		25/18	69.84±3.26	8/35		8.23±1.36		5.41±1.06		13（30.23）/30（69.77）			152.03±10.73		101.24±8.26		22（51.16）	15（34.88）
t或χ²			0.189	1.380	0.341		1.041		0.799		0.231			0.732		0.877		0.187	0.199
组别		高血脂病史		NYHA分级（Ⅰ~Ⅱ/Ⅲ~Ⅳ）		冠脉病变（单支/多支）		心率（次/min）		支架长度（mm）		支架内径（mm）	支架植入数量（个）		糖尿病史		降压药（ACEI或ARB/β 受体阻滞剂/CCB/利尿剂
对照组		28（65.12）		26/17		19/24		71.24±3.80		14.12±2.18		2.81±0.54	1.91±0.30		16（37.21）		9/24/33/15
研究组		26（60.47）		23/20		22/21		70.04±4.11		13.79±2.03		2.76±0.55	1.82±0.27		14（32.56）		8/21/30/13
t或χ²		0.199		0.427		0.420		1.406		0.726		0.425	1.462		0.205		0.079

组别	n		性别（男/女）	年龄（岁）	高血压类型（初发/既往）		高血压病程（年）		冠心病病程（年）		冠心病类型（稳定型心绞痛/ACS）			SBP （mmHg）		DBP （mmHg）		吸烟史	饮酒史
对照组	43		23/20	67.71±3.05	6/37		7.94±1.22		5.23±1.03		11（25.58）/32（74.42）			150.27±11.54		102.79±8.13		24（55.81）	17（39.53）
研究组	43		25/18	69.84±3.26	8/35		8.23±1.36		5.41±1.06		13（30.23）/30（69.77）			152.03±10.73		101.24±8.26		22（51.16）	15（34.88）
t或χ²			0.189	1.380	0.341		1.041		0.799		0.231			0.732		0.877		0.187	0.199
组别		高血脂病史		NYHA分级（Ⅰ~Ⅱ/Ⅲ~Ⅳ）		冠脉病变（单支/多支）		心率（次/min）		支架长度（mm）		支架内径（mm）	支架植入数量（个）		糖尿病史		降压药（ACEI或ARB/β 受体阻滞剂/CCB/利尿剂
对照组		28（65.12）		26/17		19/24		71.24±3.80		14.12±2.18		2.81±0.54	1.91±0.30		16（37.21）		9/24/33/15
研究组		26（60.47）		23/20		22/21		70.04±4.11		13.79±2.03		2.76±0.55	1.82±0.27		14（32.56）		8/21/30/13
t或χ²		0.199		0.427		0.420		1.406		0.726		0.425	1.462		0.205		0.079

组别	24 h SBP变异系数
组别	治疗前	治疗后	t
对照组	16.23±4.32	11.71±3.23	6.432^＊
研究组	16.29±4.20	8.88±2.34	8.320^＊＊
t	0.132	5.442^＊
组别	24 h DBP变异系数
组别	治疗前	治疗后	t
对照组	14.32±3.20	10.22±2.83	5.942^＊
研究组	14.21±3.11	7.32±2.21	9.883^＊＊
t	0.106	4.883^＊

组别	24 h SBP变异系数
组别	治疗前	治疗后	t
对照组	16.23±4.32	11.71±3.23	6.432^＊
研究组	16.29±4.20	8.88±2.34	8.320^＊＊
t	0.132	5.442^＊
组别	24 h DBP变异系数
组别	治疗前	治疗后	t
对照组	14.32±3.20	10.22±2.83	5.942^＊
研究组	14.21±3.11	7.32±2.21	9.883^＊＊
t	0.106	4.883^＊

组别	LVEF			LVMI（g/m²）			LAVI（mL/m²）
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	0.452±0.012	0.472±0.023	0.743	121.21±11.02	124.22±13.19	0.930	33.28±2.78	30.63±2.13	5.807^＊
研究组	0.453±0.015	0.522±0.118	5.342^＊	121.77±12.11	139.76±14.38	10.374^＊＊	33.10±2.64	27.38±1.84	8.794^＊＊
t	0.023	4.385^＊		0.210	8.321^＊＊		0.304	7.223^＊

Application effect research of different antihypertensive modes in elderly hypertensive patients with coronary heart disease and PCI

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

Figures/Tables 6

References 12

Related Articles 15

Recommended Articles

Metrics

Comments

组别	心动过缓	低血压	急性肾功能损害	高钾血症	不良反应发生率
对照组	1（2.38）	1（2.38）	1（2.38）	0	3（7.14）
研究组	1（2.38）	4（9.52）	2（4.76）	1（2.38）	8（19.05）
χ²	—				2.615

组别	心血管死亡	心肌梗死	脑卒中	心力衰竭再住院	心脑血管新发事件总发生率
对照组	1（2.33）	2（4.65）	3（6.98）	7（16.28）	13（30.23）
研究组	0	1（2.38）	1（2.38）	3（7.14）	5（11.90）
χ²	—				4.276^＊

[1]	WU Caixin, YAN Yan, DENG Yuanlin, DU Yamin, YANG Zhenwen, PAN Qing, YANG Fan. The value of cardiac magnetic resonance in evaluating severe pulmonary hypertension associated with connective tissue disease [J]. Tianjin Medical Journal, 2024, 52(7): 691-694.
[2]	WANG Hui, PAN Qing, WANG Zhouming, ZHANG Na, YANG Zhenwen, WEI Wei. Analysis of clinical features of mixed connective tissue disease associated with pulmonary arterial hypertension [J]. Tianjin Medical Journal, 2024, 52(7): 701-703.
[3]	LI Yong, SU Yakun, ZHANG Hongbo, LI Yuan, LI Zhanhu, YAN Xiaoju. Clinical significance of serum asprosin level in patients with early renal damage of essential hypertension [J]. Tianjin Medical Journal, 2024, 52(6): 609-613.
[4]	ZHENG Kangpeng, TANG Xinguo, XU Qi, FAN Yuting, LIANG Bo, FU Xiaowei, FANG Lu. Nomogram construction and validation for predicting the possibility successful implementation of radical surgery in gallbladder cancer patients [J]. Tianjin Medical Journal, 2024, 52(5): 536-540.
[5]	ZHANG Liran, ZHAO Yanhua. The predictive value of MP hypertension monitoring system combined with PLGF and PI for preeclampsia [J]. Tianjin Medical Journal, 2024, 52(3): 306-310.
[6]	CAO Junyang, MA Chunxing, LIU Zhina. Predictive value of vitamin and folic acid levels in gestational diabetes mellitus complicated by preeclampsia [J]. Tianjin Medical Journal, 2024, 52(12): 1278-1282.
[7]	GU Yunyun, ZHONG Chongming, YANG Haiyan. Predictive value of uric acid/albumin ratio for coronary heart disease in patients with chronic kidney disease [J]. Tianjin Medical Journal, 2024, 52(11): 1202-1206.
[8]	QIN Chundi, MA Wen, LI Yuan, ZHU Yaquan, LI Yu, ZOU Lin, ZHANG Xin. Butyrate reduces blood pressure in hypertensive rats by activating the G protein-coupled receptor 41/43 pathway [J]. Tianjin Medical Journal, 2023, 51(9): 972-976.
[9]	ZHANG Zhaoxia, NAN Xingmei, LI Zhanqiang, LU Dianxiang. Research progress on the role of potassium channels and drug intervention in hypoxic pulmonary hypertension [J]. Tianjin Medical Journal, 2023, 51(8): 892-896.
[10]	LIU Shouhong, ZHANG Yongquan, WANG Qiao. Correlation between serum ficolin and coronary artery stenosis and its influence on prognosis in patients with coronary heart disease [J]. Tianjin Medical Journal, 2023, 51(7): 776-780.
[11]	ZHANG Wenjing, WEN Dehui, ZHENG Yingjuan, LI Chaoxi, NIU Yajun, MIAO Qing. The study of QAS combined with QIMT technology on carotid atherosclerosis in patients with normal high blood pressure [J]. Tianjin Medical Journal, 2023, 51(6): 662-667.
[12]	LIU Yuanyuan, ZHANG Enyuan, WANG Chengjian, YANG Shicheng, SI Hailong, XUE Yuanyuan, ZHENG Junyi. Clinical effect of Qishen Yiqi dropping pill on the prognosis of patients with depression after percutaneous coronary intervention [J]. Tianjin Medical Journal, 2023, 51(5): 508-512.
[13]	ZHENG Yue, MA Yunting, ZHAO Xiaoying, ZHAO Xinxiang. Correlation between homocysteine and left ventricular myocardial fibrosis in hypertensive patients [J]. Tianjin Medical Journal, 2023, 51(4): 395-399.
[14]	HAN Chuyi, CONG Hongliang, WANG Le, ZHANG Jingxia. Prediction of risk factors for hypothyroidism in NSTE-ACS patients exposed to iodine contrast media [J]. Tianjin Medical Journal, 2023, 51(4): 422-426.
[15]	LIU Yanqiu, FAN Haidi, HOU Haiyan, SUN Jian, LIN Ning. Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease [J]. Tianjin Medical Journal, 2023, 51(3): 294-298.

组别	EQ-5D-3L			PHQ-9			SAS			FES-I
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	60.23±5.43	64.22±5.83	0.804	16.32±3.04	13.38±2.93	0.794	37.32±4.43	34.28±3.43	1.034	25.34±2.43	22.11±3.85	0.693
研究组	59.23±4.98	73.23±5.90	10.283^＊＊	15.29±2.32	8.22±2.33	6.802^＊	36.89±3.82	26.27±3.56	9.423^＊＊	24.89±2.11	14.29±2.95	12.332^＊＊
t	0.142	6.342^＊		0.128	4.053^＊		0.163	5.893^＊		0.324	5.334^＊

组别	EQ-5D-3L			PHQ-9			SAS			FES-I
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	60.23±5.43	64.22±5.83	0.804	16.32±3.04	13.38±2.93	0.794	37.32±4.43	34.28±3.43	1.034	25.34±2.43	22.11±3.85	0.693
研究组	59.23±4.98	73.23±5.90	10.283^＊＊	15.29±2.32	8.22±2.33	6.802^＊	36.89±3.82	26.27±3.56	9.423^＊＊	24.89±2.11	14.29±2.95	12.332^＊＊
t	0.142	6.342^＊		0.128	4.053^＊		0.163	5.893^＊		0.324	5.334^＊